🟢 Tvardi Therapeutics is trading 9.43% up in pre-market

Tvardi Therapeutics is trading at $1.39, up 9.43% in pre-market versus the September 25 close of $1.27; no confirmed catalyst was identified.

• No company announcement was found for September 28.
• The latest identified company news, published September 24, reported preclinical TTI-101 findings in a mouse model; no connection to this pre-market move was established.
• The supplied market context is broadly negative and does not explain the rise. No volume or activity data was provided.